| scholarly article | Q13442814 |
| P50 | author | Stephen B. Baylin | Q28113000 |
| Wenbing Xie | Q41634154 | ||
| Jianjun Luo | Q56769648 | ||
| Hariharan Easwaran | Q59451799 | ||
| P2093 | author name string | Zhihong Wang | |
| Yi Cai | |||
| Yana Li | |||
| Limin Xia | |||
| Ray-Whay Chiu Yen | |||
| Yang W Zhang | |||
| P2860 | cites work | Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island | Q21092482 |
| Acetylation-dependent regulation of Skp2 function | Q24292805 | ||
| Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands | Q24297794 | ||
| Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 | Q24306181 | ||
| Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation | Q24311603 | ||
| Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1 | Q24316558 | ||
| Cancer-associated IDH1 mutations produce 2-hydroxyglutarate | Q24320239 | ||
| A decade of exploring the cancer epigenome - biological and translational implications | Q24614467 | ||
| Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine | Q24614582 | ||
| Histone H3K27ac separates active from poised enhancers and predicts developmental state | Q24628758 | ||
| Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA | Q24632387 | ||
| IDH1 and IDH2 mutations in gliomas | Q24648948 | ||
| Inflammation and cancer | Q24649640 | ||
| Structure of a Naegleria Tet-like dioxygenase in complex with 5-methylcytosine DNA | Q27681187 | ||
| Histone deacetylases and cancer | Q28240447 | ||
| The epigenomics of cancer | Q28289975 | ||
| Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification | Q28504641 | ||
| Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation | Q29615366 | ||
| Genome-scale CRISPR-Cas9 knockout screening in human cells | Q29616044 | ||
| Proteomics. Tissue-based map of the human proteome | Q29617248 | ||
| Mutation in TET2 in myeloid cancers | Q29619292 | ||
| TET enzymes, TDG and the dynamics of DNA demethylation. | Q33715010 | ||
| Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation | Q34258768 | ||
| Role of Tet proteins in enhancer activity and telomere elongation | Q34271341 | ||
| The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation | Q34355585 | ||
| Mismatch repair proteins recruit DNA methyltransferase 1 to sites of oxidative DNA damage. | Q34485631 | ||
| Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation | Q34954115 | ||
| Acquired mutations in TET2 are common in myelodysplastic syndromes | Q34984094 | ||
| oxBS-450K: a method for analysing hydroxymethylation using 450K BeadChips. | Q35007310 | ||
| CRL4(VprBP) E3 ligase promotes monoubiquitylation and chromatin binding of TET dioxygenases | Q35007645 | ||
| TET proteins and the control of cytosine demethylation in cancer | Q35021377 | ||
| Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis | Q35575250 | ||
| 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations | Q35624365 | ||
| DNA methylation: TET proteins-guardians of CpG islands? | Q35634706 | ||
| Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. | Q35640316 | ||
| A DNA hypermethylation module for the stem/progenitor cell signature of cancer. | Q35914847 | ||
| Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation | Q36008141 | ||
| Acute loss of TET function results in aggressive myeloid cancer in mice | Q36360635 | ||
| Base-resolution analysis of 5-hydroxymethylcytosine in the mammalian genome. | Q36659158 | ||
| Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. | Q36815200 | ||
| Genome-wide profiling of 5-formylcytosine reveals its roles in epigenetic priming | Q36853522 | ||
| Chronic inflammation and oxidative stress in human carcinogenesis | Q36950970 | ||
| Oxidative stress, DNA methylation and carcinogenesis. | Q37121227 | ||
| TETonic shift: biological roles of TET proteins in DNA demethylation and transcription | Q37244379 | ||
| Reversing DNA methylation: mechanisms, genomics, and biological functions | Q37609689 | ||
| Interplay between the cancer genome and epigenome | Q38094260 | ||
| 5-Hydroxymethylcytosine Marks Sites of DNA Damage and Promotes Genome Stability. | Q38795786 | ||
| 5mC oxidation by Tet2 modulates enhancer activity and timing of transcriptome reprogramming during differentiation | Q38952550 | ||
| Phosphorylation of TET proteins is regulated via O-GlcNAcylation by the O-linked N-acetylglucosamine transferase (OGT). | Q41610545 | ||
| Regulation of TET protein stability by calpains. | Q42998566 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 2 | |
| P921 | main subject | DNA methylation | Q874745 |
| P304 | page(s) | 323-335 | |
| P577 | publication date | 2017-01-01 | |
| P1433 | published in | Molecular Cell | Q3319468 |
| P1476 | title | Acetylation Enhances TET2 Function in Protecting against Abnormal DNA Methylation during Oxidative Stress | |
| P478 | volume | 65 |
| Q47251165 | A KDM5 Inhibitor Increases Global H3K4 Trimethylation Occupancy and Enhances the Biological Efficacy of 5-Aza-2'-Deoxycytidine |
| Q100465117 | Active turnover of DNA methylation during cell fate decisions |
| Q90482750 | Advances in targeted therapy for malignant lymphoma |
| Q41634104 | CHD4 Has Oncogenic Functions in Initiating and Maintaining Epigenetic Suppression of Multiple Tumor Suppressor Genes |
| Q55364605 | Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions-benign adenomas and inflammatory bowel disease. |
| Q99207639 | Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia |
| Q64944255 | DNA Methylation of Mouse Testes, Cardiac and Lung Tissue During Long-Term Microgravity Simulation. |
| Q39455821 | DNA Oncogenic Virus-Induced Oxidative Stress, Genomic Damage, and Aberrant Epigenetic Alterations |
| Q92573217 | Decreased DNA methyltransferases expression is associated with coronary artery lesion formation in Kawasaki disease |
| Q52714605 | Endonuclease G promotes mitochondrial genome cleavage and replication. |
| Q58777465 | Environmental Enrichment Improves Cognitive Deficits, AD Hallmarks and Epigenetic Alterations Presented in 5xFAD Mouse Model |
| Q64082383 | Gene activation precedes DNA demethylation in response to infection in human dendritic cells |
| Q90926975 | Glucose-Regulated TET2 Activity Links Cancer to Diabetes |
| Q60585008 | In vivo evidence of ascorbate involvement in the generation of epigenetic DNA modifications in leukocytes from patients with colorectal carcinoma, benign adenoma and inflammatory bowel disease |
| Q61801946 | Invariant phenotype and molecular association of biallelic mutant myeloid neoplasia |
| Q57024647 | North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies |
| Q45989245 | Oxidative Modifications in Tissue Pathology and Autoimmune Disease. |
| Q98463502 | Pancreatic cancers suppress negative feedback of glucose transport to reprogram chromatin for metastasis |
| Q64994201 | Phosphorylation of TET2 by AMPK is indispensable in myogenic differentiation. |
| Q92853790 | Promising Directions in Atherosclerosis Treatment Based on Epigenetic Regulation Using MicroRNAs and Long Noncoding RNAs |
| Q58606027 | SNIP1 Recruits TET2 to Regulate c-MYC Target Genes and Cellular DNA Damage Response |
| Q64252242 | TET Enzymes and 5hmC in Adaptive and Innate Immune Systems |
| Q99608172 | TET is targeted for proteasomal degradation by the PHD-pVHL pathway to reduce DNA hydroxymethylation |
| Q39337480 | TET-mediated active DNA demethylation: mechanism, function and beyond |
| Q91842547 | TET2 binding to enhancers facilitates transcription factor recruitment in hematopoietic cells |
| Q57053271 | TET2 deficiency causes germinal center hyperplasia, impairs plasma cell differentiation and promotes B-cell lymphomagenesis |
| Q92675877 | TET2 missense variants in human neoplasia. A proposal of structural and functional classification |
| Q98288422 | TET2 suppresses nasopharyngeal carcinoma progression by inhibiting glycolysis metabolism |
| Q90950040 | TET2-interacting long noncoding RNA promotes active DNA demethylation of the MMP-9 promoter in diabetic wound healing |
| Q52589797 | TET2: A Novel Epigenetic Regulator and Potential Intervention Target for Atherosclerosis. |
| Q88721038 | Ten-eleven translocation 2 demethylates the MMP9 promoter, and its down-regulation in preeclampsia impairs trophoblast migration and invasion |
| Q91666337 | Testes and duct deferens of mice during space flight: cytoskeleton structure, sperm-specific proteins and epigenetic events |
| Q47390065 | The Loss of TET2 Promotes CD8+ T Cell Memory Differentiation |
| Q64214332 | The emerging role of epigenetic modifiers in repair of DNA damage associated with chronic inflammatory diseases |
| Q90709725 | The epigenetically-encoded memory of the innate immune system |
| Q47146944 | Uncoordinated expression of DNA methylation-related enzymes in human cancer. |
| Q58617722 | p53-dependent autophagic degradation of TET2 modulates cancer therapeutic resistance |
Search more.